Coalition Expects Higher Personalized Medicine Profile During User Fee Talks
This article was originally published in The Gray Sheet
Executive Summary
Better coordination of device and drug review processes is crucial to the future of personalized medicine and are likely to be an important focus of upcoming user fee negotiations, says the Personalized Medicine Coalition's Amy Miller.
You may also be interested in...
Calls For More FDA Training In Lead Up To User-Fee Negotiations
Device firms will be pushing for more reviewer consistency and to avoid a major increase in fees during upcoming negotiations with FDA to reauthorize the Medical Device User Fee Act. The MDUFA IV reauthorization process starts as Congress is already considering major regulatory reforms and will finish under a new administration in the White House.
Combo Product Reforms Are A Priority For Next User Fee Round, FDA Officials Say
Top FDA officials, including CDRH Director Jeffrey Shuren and FDA Deputy Commissioner Robert Califf, are sending strong signals that the designation and review processes for combination products are due for a significant reassessment. That should be a priority topic of upcoming user fee negotiations with industry, they say.
Senators Circulate Plan For Standalone FDA Diagnostics Center, ‘In Vitro Clinical Test’ Rules
Senators are drafting legislation to create a standalone FDA Center to oversee diagnostics, including IVDs and LDTs, under a framework distinct from current medical device regulations.